Telaprevir: An oral protease inhibitor for hepatitis C virus infection

American Journal of Health-System Pharmacy

Volumn 69, Issue 1, 2012, Pages 19-33

  Kim, Jenny J ^a   Culley, Colleen M ^b,c   Mohammad, Rima A ^c,d  

^a SHENANDOAH UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d U of WI School of Pharmacy   (United States)

Author keywords

Antivirals; Combined therapy; Dosage; Drug administration; Drug interactions; Hepatitis C; Mechanism of action; Peginterferon alfa; Pharmacodynamics; Pharmacokinetics; Resistance; Ribavirin; Telaprevir; Toxicity

Indexed keywords

ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ATAZANAVIR; CYCLOSPORIN; CYTOCHROME P450 3A4; DARUNAVIR; DEXAMETHASONE; FOSAMPRENAVIR; GLYCOPROTEIN P; HEMOGLOBIN; KETOCONAZOLE; LOPINAVIR; OROSOMUCOID; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; RIFABUTIN; RITONAVIR; RNA; TACROLIMUS; TELAPREVIR;

ANEMIA; ANORECTAL DISEASE; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; COMPARATIVE STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSGEUSIA; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC ANEMIA; HEMORRHOID; HEPATITIS C; HUMAN; IC 50; LIVER CIRRHOSIS; LIVER DISEASE; MONOTHERAPY; NAUSEA; NEUTROPHIL COUNT; PHARMACOGENOMICS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS LOAD; VIRUS REPLICATION; VOMITING;

EID: 84855263813     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110123     Document Type: Review

References (42)

1. Williams R. Global challenges in liver disease. Hepatology. 2006; 44:521-6. (Pubitemid 44433707)
2. Centers for Disease Control and Prevention. Hepatitis C FAQs for health professionals. Index of questions. www.cdc.gov/ hepatitis/HCV/HCVfaq. htm#section1 (accessed 2010 Oct 17).
3. Barnes E. The need for an HCV vaccine. WHO factsheet 2010. www.who.int/ vaccine-research/diseases/viral-cancers/ en/index2.html (accessed 2010 Dec 15).
4. Ghany MG, Strader DB, Thomas DL et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49:1335-74.
5. Nainan OV, Alter MJ, Kruszon-Moran D et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology. 2006; 131:478- 84.
6. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358:958-65. (Pubitemid 32913521)
7. Fried MW, Shiffman ML, Reddy R et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347:975-82.
8. Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140:346-55.
9. Farnik H, Lange CM, Sarrazin C et al. Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol. 2010; 8:884-90.
10. Kronenberger B, Zeuzem S. Current and future treatment options for HCV. Ann Hepatol. 2009; 8:103-12.
11. Francesco RD, Carfi A. Advances in the development of new therapeutic agents targeting the NS3-4A serine protease of the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv Drug Deliv Rev. 2007; 59:1242-62. (Pubitemid 350047514)
12. Kwo PY, Lawitz EJ, McCone J et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010; 376:705-16.
13. Victrelis (boceprevir) package insert. Whitehouse Station, NJ: Schering Corporation; 2011 May.
14. Incivek (telaprevir) package insert. Cambridge, MA: Vertex Pharmaceuticals Inc.; 2011 May.
15. Perni RB, Almquist S, Byrn RA et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3/4A serine protease. Antimicrob Agents Chemother. 2006; 50:899-909. (Pubitemid 43327793)
16. Kieffer TL, Kwong AD, Picchio GR. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother. 2010; 65:202-12.
17. Reesink HW, Zeuzem S, Weegink CJ et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase 1b, placebo-controlled, randomized study. Gastroenterology. 2006; 131:997-1002.
18. Forestier N, Reesink HW, Weegink CJ et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology. 2007; 46:640-8. (Pubitemid 47436108)
19. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461:399-401.
20. Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461:798-802.
21. Fellay J, Thompson AJ, Ge D et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010; 464:405-8.
22. Thompson AJ, Fellay J, Patel K et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology. 2010; 139:1181-9.
23. Ochi H, Maekawa T, Abe H et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy - a genome-wide study of Japanese HCV virus patients. Gastroenterology. 2010; 139:1190-7.
24. Chayama K, Hayes CN, Abe H et al. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis. 2011; 204:84-93.
25. Lawitz E, Rodriguez-Torres M, Muir A et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol. 2008; 49:163-9.
26. McHutchison JG, Everson GT, Gordon SC et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009; 360:1827-38.
27. Hézode C, Forestier N, Dusheiko G et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009; 360:1839-50.
28. McHutchison JG, Manns MP, Muir AJ et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010; 362:1292-303. [Erratum, N Engl J Med. 362:1647.]
29. Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364:2405-16.
30. Sherman KE, Flamm SL, Afdhal NH et al. Telaprevir in combination with peg-interferon alfa2a and ribavirin for 24 or 48 weeks in treatment-naïve genotype 1 HCV patients who achieved an extended rapid viral response: final results of phase 3 ILLUMINATE study (abstract LB-2). Presented at 61st Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA; 2010 Oct.
31. Zeuzem S, Andreone P, Pol S et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011; 364:2417-28.
32. Foster GR, Hezode C, Bronowicki JP et al. Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naïve genotype 2 and 3 hepatitis-C patients: final results of study C209. Presented at 45th Annual Meeting of the European Association for the Study of the Liver. Vienna, Austria; 2010 Apr.
33. Marcellin P, Forns X, Goeser T et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology. 2011; 140:459-68.
34. Montaudié H, Passeron T, Cardot-Leccia N et al. Drug rash with eosinophilia and systemic symptoms due to telaprevir. Dermatology. 2010; 221:303-5.
35. Seden K, Back D, Khoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. J Antimicrob Chemother. 2010; 65:1079- 85.
36. Kempf D, Klein C, Chen HB et al. Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir. Antivir Chem Chemother. 2007; 18:163-7. (Pubitemid 47167768)
37. Garg V, van Heeswijk R, Lee JE et al. The effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 2011; 54:20-7.
38. Sarrazin C, Kieffer TL, Bartels D et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007; 132:1767- 77.
39. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology. 2010; 138:447-62.
40. Susser S, Welsch C, Wang Y et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology. 2009; 50:1709-18.
41. Kuntzen T, Timm J, Berical A et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology. 2008; 48:1769-78.
42. Imhof I, Simmonds P. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology. 2011; 53:1090-9.